Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (9995)	10/23/2008 9:33:52 PM
From: zeta1961	2 Recommendations of 10345

Yes IJ, it's the side effects; from it's high immunogenicity to its blood component depression(and the feeling lousy they impart)..I note some patients developed ITP and one patient died of it...don't like T cells being obliterated because they take a long time to reconstitute, yet it's dosed just once a year...dunno... I'da had a hard time letting someone I care about, in the early phases of their MS like this study recruited, to enroll..these are tough decisions and Tysabri has had its PML cloud... Edit: I just plain think that "we" could do better for MS patients than reconstituting an old drug with lousy side effects and charging outrageous amts of money for it...........

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next